Article

Using Blood Lactate Level to Assess CCU Patients

Author(s):

Blood lactate levels can predict short-term prognosis in patients who have had primary percutaneous coronary interventions after an acute myocardial infarction

Blood lactate levels can predict short-term prognosis in patients who have had primary percutaneous coronary interventions after an acute myocardial infarction.

In research to be presented April 2 at the American College of Cardiology 65th Scientific Session & Expo in Chicago, IL, Hirohide Matsuura and colleagues from Myazaki Medical Association Hospital Cardiovascular Center, Miyazaki, Japan, reported on these levels in coronary care unit patients.

Hyperlactatemia has been known as a simple marker of poor prognosis in various acutely ill patient, they wrote. The team set out to see what happened to those levels, hemodynamic parameters and short-term mortality in patients who had had a primary percutaneous coronary intervention after an acute myocardial infarction (AMI).

They followed 374 such patients in their hospital, dividing them according to lactate levels after PCI.

They found the higher the lactate level while they were in the coronary care unit, the higher their in-hospital mortality.

"One-point measurement of blood lactate level after PCI might be beneficial as a short-term prognostic predictor in AMI," they concluded.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.